Southern China Urology Cancer Consortium
1 clinical trials · Sponsor
◉ Watch Southern China Urology Cancer Consortium
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients (NCT02324803) | Southern China Urology Cancer Consortium | 2014-07-01 |
Track Southern China Urology Cancer Consortium automatically
Every clearance here is in the API, with alerts when new ones post.